Biovista Enters Drug Repositioning Collaboration with Astellas Pharma

Biovista has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) technology.

"We look forward to working with the Drug Repurposing and Application Management at Astellas to compliment their work," said Dr.Aris Persidis, President of Biovista. "Our very large scale systematic drug repositioning technology the "Clinical Outcome Search Space - COSS(tm) offers the advantages of speed, comprehensiveness and depth of clinical outcome exploration, which we hope will help patients in need benefit even more from Astellas drugs," he added.